Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)
NCT02502253Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Jun 2015
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of bioactive dietary polyphenol preparation in Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD) (3 arms), sponsored by Johns Hopkins University. Primary endpoints: Assessment of Adverse Events and Serious Adverse Events at 4 months, Levels of BDPP constituents in cerebrospinal fluid at 4 months and 2 more. Started Jun 2015; status: completed.
02
Drugs
bioactive dietary polyphenol preparation
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02502253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502253.